U.S. markets open in 3 hours 12 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
63.18+0.94 (+1.51%)
At close: 04:00PM EDT
62.70 -0.48 (-0.76%)
Pre-Market: 05:03AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close62.24
Bid0.00 x 900
Ask0.00 x 800
Day's Range61.80 - 63.21
52 Week Range57.19 - 74.12
Avg. Volume9,910,063
Market Cap79.247B
Beta (5Y Monthly)0.42
PE Ratio (TTM)17.65
EPS (TTM)3.58
Earnings DateJul 27, 2022 - Aug 01, 2022
Forward Dividend & Yield2.92 (4.62%)
Ex-Dividend DateJun 14, 2022
1y Target Est69.35
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
32% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GILD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gilead Sciences, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a California-based biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 14,400 employees.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more